Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000079385 | SCV000111264 | benign | not specified | 2013-05-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000720984 | SCV000851868 | uncertain significance | History of neurodevelopmental disorder | 2013-12-26 | criteria provided, single submitter | clinical testing | The p.K236R variant (also known as c.707A>G), located in coding exon 4 of the ZNF674 gene, results from an A to G substitution at nucleotide position 707. The lysine at codon 236 is replaced by arginine, an amino acid with highly similar properties. This variant was previously reported in the SNPDatabase as rs201621696. Based on data from the NHLBI Exome Sequencing Project (ESP), the G allele has an overall frequency of approximately 0.58% (13/2230) total male alleles studied having been observed in 0.77% (13/1680) European American male alleles but absent out of 550 African American male alleles studied. This amino acid position is not conserved on species alignment. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. |
Prevention |
RCV003925046 | SCV004741897 | benign | ZNF674-related disorder | 2019-05-16 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |